Tricida (NASDAQ:TCDA) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Tricida (NASDAQ:TCDA) from a sell rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Tricida, Inc. is a late-stage pharmaceutical company. It focuses on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular diseases. The company’s product candidate consists of TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. Tricida, Inc. is based in CA, United States. “

TCDA has been the topic of a number of other reports. Needham & Company LLC set a $50.00 price objective on shares of Tricida and gave the stock a buy rating in a report on Monday, August 12th. Goldman Sachs Group began coverage on shares of Tricida in a report on Wednesday, June 26th. They set a buy rating and a $48.00 price objective on the stock. Finally, Cowen reissued a buy rating and issued a $50.00 price target on shares of Tricida in a report on Thursday, August 8th.

TCDA opened at $34.27 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 14.23 and a quick ratio of 14.22. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.39 and a beta of 0.90. The firm’s fifty day moving average price is $33.16 and its two-hundred day moving average price is $31.63. Tricida has a 1 year low of $19.43 and a 1 year high of $42.80.

Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.12. As a group, equities analysts anticipate that Tricida will post -3.54 EPS for the current year.

In related news, insider Geoffrey M. Parker purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were bought at an average cost of $32.33 per share, with a total value of $969,900.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Claire Lockey sold 40,401 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $37.10, for a total transaction of $1,498,877.10. The disclosure for this sale can be found here. Insiders sold a total of 90,126 shares of company stock worth $3,218,846 over the last three months. 66.70% of the stock is owned by insiders.

Several large investors have recently modified their holdings of TCDA. International Biotechnology Trust PLC increased its position in shares of Tricida by 4.9% during the second quarter. International Biotechnology Trust PLC now owns 20,000 shares of the company’s stock valued at $788,000 after buying an additional 934 shares during the period. Orbimed Advisors LLC increased its position in shares of Tricida by 2.1% during the second quarter. Orbimed Advisors LLC now owns 11,114,280 shares of the company’s stock valued at $438,569,000 after buying an additional 225,000 shares during the period. Royal Bank of Canada increased its position in shares of Tricida by 356.3% during the second quarter. Royal Bank of Canada now owns 5,475 shares of the company’s stock valued at $216,000 after buying an additional 4,275 shares during the period. University of Notre Dame DU Lac bought a new stake in shares of Tricida during the second quarter valued at about $4,044,000. Finally, MAI Capital Management increased its position in shares of Tricida by 54.0% during the second quarter. MAI Capital Management now owns 17,035 shares of the company’s stock valued at $672,000 after buying an additional 5,971 shares during the period. 64.56% of the stock is currently owned by institutional investors.

Tricida Company Profile

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Featured Story: Technical Analysis

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.